**TRANSCEND Project Meeting  
September 14, 2011**

**Attendees:**

Sarah Davis, UCSF  
Mervi Heiskanen, NCI  
Shine Jacob, NCI  
Juli Klemm, NCI  
Rashmi Srinivasa, NCI  
Eve Shalley, NCI

**Meeting purpose**: The caArray and caIntegrator technical teams discussed the requirements for 2TRANSCEND to get more clarity around capabilities discussed in previous meetings.

***Clarification on permissions:***

The team indicated that they are clear on permissions related to patient-level and clinical notations, but need more understanding around sample level and data type permissions.

Q: Is permission at data type level, or at an even more refined level of detail?

A: Similar to how we are limiting patients clinically, by treatment arm, that same role-based security would apply across all platforms. Also, we would only allow one type of platform to be available per patient.

Q: Is there a need to define access based on platform, or just on patient?

A: These additional levels of permissions are required.

Q: What about sample level? A patient has samples for a specific study.

A: Within I-SPY we take samples throughout the course the study, so one investigator might only be able to see Timepoint 1 samples. This needs to be the same in caArray and caIntegrator.

Q: As study manager, you create a study with all the data mixed together. So we are talking about filtering on the study level, but when you have a specific user who has only certain access, when that user uses caIntegrator they can only query that data.

A: Yes.

Q: We’ve been talking about an investigator in caIntegrator, so will this have to work the same way in caArray.

A: Ideally, yes. Some investigators will have access to everything and we are looking to provide access to the raw data as well as the normalized data.

Q: The authorization is desired based on array type, not on platform type. For example, all gene expression in which there could be multiple platform types that do gene expression.

A: Yes, security by array type. That may be subject to change. Is it easier to make it so that as the study manager they would have to select all the types within that platform, rather than saying users can have access to all of that type? That would be my preferred option, to have it by platform.

A: That is probably easier. There would be security by array type, but in the future it may be by experiment type.

Q: What platforms will be used? We are working to support many platforms and want to be sure those you need are included.

A: Agilent 44 gene expression array. We are also looking at the Affy U133A array. Those are the only two gene expression we are looking at currently. CGH is also being considered.

Q: How critical is version control?

A: It would be great to have that in the first phase, if possible.

Q: How often to you load new experiments into caArray?

A: At most, once per month.